Table 1.
Study Number | N | Study Design/Agent | Description |
---|---|---|---|
NCT0086230350 | 100 | Randomized phase I/II DC-CIK IL-2/IFN-α |
|
NCT0152282051 | 20 | Phase I Sirolimus DEC-205-NY-ESO-1 fusion protein vaccine |
|
NCT0091391352 | 24 | Phase 2 DC vaccine Bevacizumab IL-2 IFN-α |
|